Stock SYNTA PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Synta Pharmaceuticals Corp. Stock Nasdaq

Equities

US87162T2069

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Synta Pharmaceuticals Corp.
Apr. 22 BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
Apr. 22 BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT

Financials (USD)

Sales 2024 * 81.74M Sales 2025 * 351M Capitalization 4.08B
Net income 2024 * -459M Net income 2025 * -296M EV / Sales 2024 * 48.8 x
Net cash position 2024 * 93.53M Net Debt 2025 * 116M EV / Sales 2025 * 11.9 x
P/E ratio 2024 *
-8.35 x
P/E ratio 2025 *
-13.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.04%
More Fundamentals * Assessed data

Latest news about Synta Pharmaceuticals Corp.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Says Rezdiffra Available in US MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering MT
Madrigal Pharmaceuticals Starts $500 Million Public Offering MT
Madrigal plans $500 million fund raising to prepare for NASH drug launch RE
Madrigal commences $500 million public offering of common stock RE
More news

Latest transcript on Synta Pharmaceuticals Corp.

Logo Synta Pharmaceuticals Corp.
Madrigal Pharmaceuticals, Inc. - Special Call
More transcripts

Analyst Recommendations on Synta Pharmaceuticals Corp.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing MT
More recommendations

Press releases Synta Pharmaceuticals Corp.

Madrigal Statement on the Passing of Dr. Stephen Harrison AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 AQ
6 Stocks Positioned to Soar as Investors Focus on MASH AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) AQ
More press releases

News in other languages on Synta Pharmaceuticals Corp.

EE.UU. - Valores a seguir en Wall Street (actualizado)
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -
Madrigal Pharmaceuticals : lève 600 millions de dollars pour le lancement de son Rezdiffra
Wall Street ouvre en baisse, les regards tournés vers la Fed
EE.UU. - Valores a seguir en Wall Street (actualizado)
More news

Managers and Directors - Synta Pharmaceuticals Corp.

Managers TitleAgeSince
Edward Chiang FOU
 Founder - 11-08-31
William Sibold CEO
 Chief Executive Officer - 23-09-07
Rebecca Taub FOU
 Founder 71 16-06-30
Members of the board TitleAgeSince
Fred Bernard Craves FOU
 Founder 78 11-08-31
Julian Baker CHM
 Chairman 57 23-06-14
Ken Bate BRD
 Director/Board Member 73 16-07-21
More insiders

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
Biotechnology & Medical Research
Calendar
2024-05-07 - Q1 2024 Earnings Release
Related indices
Russell 2000
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 97.42B
ARGENX SE Stock argenx SE
+0.79% 22.2B
BIONTECH SE Stock BioNTech SE
-17.84% 21.23B
GENMAB A/S Stock Genmab A/S
-11.11% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. Stock